Indivior (INDV) Competitors $24.32 +0.27 (+1.12%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$24.18 -0.14 (-0.58%) As of 08/22/2025 07:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock INDV vs. ATNFW, LBPSW, AEHAW, AIMDW, ALVOW, ARAV, ACABW, BFRIW, BTMDW, and BCTXWShould you be buying Indivior stock or one of its competitors? The main competitors of Indivior include 180 Life Sciences (ATNFW), 4D pharma (LBPSW), Aesther Healthcare Acquisition (AEHAW), Ainos (AIMDW), Alvotech (ALVOW), ARAVIVE (ARAV), Atlantic Coastal Acquisition Corp. II (ACABW), Biofrontera (BFRIW), biote (BTMDW), and BriaCell Therapeutics (BCTXW). These companies are all part of the "pharmaceutical products" industry. Indivior vs. Its Competitors 180 Life Sciences 4D pharma Aesther Healthcare Acquisition Ainos Alvotech ARAVIVE Atlantic Coastal Acquisition Corp. II Biofrontera biote BriaCell Therapeutics 180 Life Sciences (NASDAQ:ATNFW) and Indivior (NASDAQ:INDV) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, media sentiment, valuation, risk, earnings, profitability, institutional ownership and analyst recommendations. Does the media prefer ATNFW or INDV? In the previous week, Indivior had 3 more articles in the media than 180 Life Sciences. MarketBeat recorded 3 mentions for Indivior and 0 mentions for 180 Life Sciences. 180 Life Sciences' average media sentiment score of 0.00 equaled Indivior'saverage media sentiment score. Company Overall Sentiment 180 Life Sciences Neutral Indivior Neutral Is ATNFW or INDV more profitable? Indivior has a net margin of 6.65% compared to 180 Life Sciences' net margin of 0.00%. 180 Life Sciences' return on equity of 0.00% beat Indivior's return on equity.Company Net Margins Return on Equity Return on Assets 180 Life SciencesN/A N/A N/A Indivior 6.65%-86.28%16.26% Do analysts rate ATNFW or INDV? Indivior has a consensus target price of $19.60, indicating a potential downside of 19.41%. Given Indivior's stronger consensus rating and higher probable upside, analysts plainly believe Indivior is more favorable than 180 Life Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score 180 Life Sciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Indivior 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17 Do institutionals and insiders believe in ATNFW or INDV? 60.3% of Indivior shares are owned by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Which has preferable valuation and earnings, ATNFW or INDV? Indivior has higher revenue and earnings than 180 Life Sciences. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio180 Life SciencesN/AN/AN/AN/AN/AIndivior$1.19BN/A$2M$0.6239.23 SummaryIndivior beats 180 Life Sciences on 9 of the 10 factors compared between the two stocks. Get Indivior News Delivered to You Automatically Sign up to receive the latest news and ratings for INDV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding INDV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INDV vs. The Competition Export to ExcelMetricIndiviorMED IndustryMedical SectorNASDAQ ExchangeMarket CapN/A$2.54B$5.82B$9.76BDividend YieldN/A1.67%4.40%4.04%P/E Ratio39.2322.7131.3826.05Price / SalesN/A752.44472.41122.40Price / Cash13.3626.0925.7828.78Price / Book-9.655.599.526.07Net Income$2M$31.83M$3.26B$265.39M7 Day Performance3.67%1.89%2.14%2.00%1 Month Performance44.68%1.62%3.22%0.46%1 Year Performance97.72%9.25%30.19%18.88% Indivior Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INDVIndivior1.707 of 5 stars$24.32+1.1%$19.60-19.4%+97.7%$0.00$1.19B39.231,051ATNFW180 Life SciencesN/A$0.43-6.5%N/A+2,400.6%$0.00N/A0.007Positive NewsGap DownHigh Trading VolumeLBPSW4D pharmaN/AN/AN/AN/A$0.00$522K0.00N/AAEHAWAesther Healthcare AcquisitionN/A$0.00flatN/AN/A$0.00N/A0.002AIMDWAinosN/A$0.50+6.4%N/AN/A$0.00$106.21K0.0040Gap UpALVOWAlvotechN/A$1.31+13.9%N/A-60.6%$0.00$560.10M0.004News CoveragePositive NewsGap UpARAVARAVIVEN/A$0.04flatN/AN/A$0.00$9.14M0.0020High Trading VolumeACABWAtlantic Coastal Acquisition Corp. IIN/A$0.04-30.5%N/A-37.3%$0.00N/A0.0015BFRIWBiofronteraN/A$0.12+21.3%N/AN/A$0.00$38.00M0.0070Positive NewsGap UpBTMDWbioteN/A$0.01+26.6%N/A-95.5%$0.00$199.07M0.00N/AGap UpBCTXWBriaCell TherapeuticsN/A$0.03+18.9%N/A-94.8%$0.00N/A0.008Positive News Related Companies and Tools Related Companies ATNFW Alternatives LBPSW Alternatives AEHAW Alternatives AIMDW Alternatives ALVOW Alternatives ARAV Alternatives ACABW Alternatives BFRIW Alternatives BTMDW Alternatives BCTXW Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:INDV) was last updated on 8/24/2025 by MarketBeat.com Staff From Our PartnersIs This Stock the 'Next Nvidia'?'AI Bottleneck' Now Threatens Entire Magnificent 7 A new critical failure has appeared in the AI market, an...Altimetry | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredTrump’s “new dollar” could shock Americans"I Made Millions in the Tech Boom. Here's Where I'd Put My Money Today" This man has called some of the big...Stansberry Research | SponsoredHere's the last trade you should make before heading out for the weekend tomorrow.On a quiet Friday afternoon, one trader spotted an overlooked stock. He bought shares. He shut down his ...Timothy Sykes | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Indivior PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Indivior With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access